/ /

Ophthalmology Times Staff Reports
Let's talk about antibiotic resistance: Survey results
Ophthalmology Times asked readers for insights on antibiotics and eye infections from clinicians in the field — including experience with postoperative infections after eye surgery, if you use topical antibiotic prior to cataract surgery, how you choose antibiotics in a routine surgical prophylaxis, and more. The 118 U.S.-based ophthalmologists who responded were entered into a drawing to win a $200 gift card. Here are the survey results.
6 things PCPs should know about diabetic vision loss
The Centers for Disease Control and Prevention (CDC) estimates that 29.1 million people, or 9.3% of the U.S. population, have diabetes. Over 8 million (27.8%) have the disease and are not diagnosed. The number of diagnosed cases are projected to increase 165% from the year 2000 to 2050, according to the American Diabetes Association. By 2050, there will be 29 million diagnosed cases of diabetes in the United States.
Cataract app helps surgeons customize IOL selection
Bausch + Lomb and IBM announced a collaboration to develop the first app of its kind for iPhone and iPad for surgeons who perform cataract surgery.
Mining data for anti-VEGF therapy insights in PCV
Real-world evidence confirms the benefits of intravitreous ranibizumab (Lucentis, Genentech) for treatment of neovascular age-related macular degeneration (nAMD)—regardless of polypoidal choroidal vasculopathy (PCV) status.
DME therapy with plasma kallikrein inhibitor showing promise
Results from a phase I study of KVD001 (KalVista Pharmaceuticals) for the treatment of central involved diabetic macular edema (CIDME) show that this plasma kallikrein inhibitor was well-tolerated, not associated with any ophthalmic or systemic safety signals, and led to fairly long-lasting improvements in visual acuity (VA) and central retinal thickness (CRT) after a single intravitreous injection.
Mylan Inc. accused of patent infringement
Alcon Research Ltd. has accused Mylan Inc. of seeking government approval for a drug that would infringe three of its patents for a glaucoma treatment.
Omeros seeks new drug approval for ILR surgery
Omeros Corp. has announced that it recently submitted a new drug application to the FDA for approval of a new drug for use in patients undergoing IOL replacement (ILR) surgery.
New iFusion combination system receives FDA clearance
Optovue Inc. has received FDA 510 (k) clearance for its new iFusion combination system and has begun filing customer orders worldwide.
French commission favors reimbursement of Iluvien
The Transparency Commission of the French National Authority for Health has issued a favorable opinion for the reimbursement and hospital listing of Alimera Sciences’ fluocinolone acetonide intravitreal implant (Iluvien) for the treatment of chronic diabetic macular edema.
Topcon PASCAL Synthesis laser gets 510(k) clearance
Topcon Medical Laser Systems has received FDA 510(k) clearance for its portable, dual-port, pattern-scanning laser (PASCAL Synthesis).


View Results